

To receive your CME Credit & Certificate you must complete, sign and turn in this Evaluation Form to the Registration Desk before you leave the conference. Very important – please include your name, email, and signature.

You must indicate which sessions you attended in the Evaluation of Presentations section in order to receive credit.

Your CME certificate will be emailed from NACE within 4 weeks.

NAME (please print clearly):	DEGREE:
EMAIL ADDRESS (please print clearly):	
I hereby certify that I attended the sessions indicated below.	
➔ SIGNATURE:	DATE:

EVALUATION OF PRESENTATIONS

For each presentation listed, please complete the following:

1. Indicate each session you attended.
2. Evaluate the effectiveness of each speaker from 1 (Poor) ➔ 5 (Outstanding).
3. Choose one answer from the choices below that describes your competence level.
 - (A) I was already able to demonstrate the information covered in this presentation.
 - (B) I need to learn more before integrating the information presented in my practice.
 - (C) I am now ready to try applying this knowledge to my practice.

FRIDAY, APRIL 24, 2015		Did you attend session?	Speaker Review: 1 (Poor) ➔ 5 (Outstanding):	My competence level: (according to choices above)
Conference Welcome, <i>Mark Abdelmalek, MD</i>	10	(Y) (N)	(1) (2) (3) (4) (5)	
Acne & Rosacea Update, <i>Guy Webster, MD, PhD</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Screening for Psoriasis Patients, <i>Abby S. Van Voorhees, MD</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Cardiovascular Risk in Psoriasis, <i>Joel M. Gelfand, MD, MSCE</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Frontiers in Dermatology, <i>Herbert B. Allen, MD</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Question and Answer	10	(Y) (N)		
What's New in Pediatric Dermatology, <i>James R. Treat, MD</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Cutaneous Lupus Erythematosus, <i>Victoria P. Werth, MD</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
What's New in Pemphigus Therapy?, <i>Aimee S. Payne, MD, PhD</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
AAD Update, <i>Mark Lebwohl, MD</i>	5	(Y) (N)	(1) (2) (3) (4) (5)	
Question and Answer	10	(Y) (N)		
How to Read a Paper, <i>Joslyn S. Kirby, MD, MS</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Vasculitis: A Practical Approach, <i>Robert G. Micheletti, MD</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
HHV 6 & 7: Pathogenic in DRESS Syndrome?, <i>Warren R. Heymann, MD</i>	20	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
HIV Dermatology in the Modern Era, <i>Misha M. Mutizwa, MD</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Clinical Cases of Chronic Itch, <i>Gil Yosipovitch, MD</i>	15	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Question and Answer	10	(Y) (N)		
SATURDAY, APRIL 25, 2015		Did you attend session?	Speaker Review: 1 (Poor) ➔ 5 (Outstanding):	My competence level: (according to choices above)
Live Patient Viewing	180	(Y) (N)		
ADC Conference Update and 2016 ADC Baltimore Update, <i>Jeffery J. Miller, MD and Sewon Kang, MD</i>	30	(Y) (N)	(1) (2) (3) (4) (5)	
Patient Viewing Discussion Part I	90	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)
Patient Viewing Discussion Part II	130	(Y) (N)	(1) (2) (3) (4) (5)	(A) (B) (C)

SUNDAY, APRIL 26, 2015		Did you attend session?	Speaker Review: 1 (Poor) → 5 (Outstanding):	My competence level: (according to choices above)
Nail Unit Biopsy Techniques, Adam I. Rubin, MD	15	Y N	① ② ③ ④ ⑤	A B C
Dermatopathology Update, Rosalie Elenitsas, MD	15	Y N	① ② ③ ④ ⑤	A B C
Dermatoscopy, Jason Lee, MD	15	Y N	① ② ③ ④ ⑤	A B C
When to Transplant a Patient with a History of Skin Cancer, Christina Lee Chung, MD	15	Y N	① ② ③ ④ ⑤	A B C
New Understanding of Androgenetic Alopecia, George Cotsarelis, MD	15	Y N	① ② ③ ④ ⑤	A B C
Question and Answer	15	Y N		
Advances in Systemic Therapy for Melanoma, Tara Gangadhar, MD	15	Y N	① ② ③ ④ ⑤	A B C
Looking Beyond Thickness in Melanoma Management, Michael E. Ming, MD, MSCE	15	Y N	① ② ③ ④ ⑤	A B C
Genetic Testing for Melanoma, Emily Y. Chu, MD, PhD	15	Y N	① ② ③ ④ ⑤	A B C
Practical Issues in the Management of Melanoma, Christopher J. Miller, MD	15	Y N	① ② ③ ④ ⑤	A B C
Question and Answer	10	Y N		
Immunopathogenesis of CTCL, Alain Rook, MD	15	Y N	① ② ③ ④ ⑤	A B C
The Challenges of Managing Advanced CTCL, Ellen J. Kim, MD	15	Y N	① ② ③ ④ ⑤	A B C
Question and Answer	10	Y N		
A 3-D Approach to Facial Rejuvenation, Anthony V. Benedetto, DO, FACP	15	Y N	① ② ③ ④ ⑤	A B C
Laser Complications, Nazanin Saedi, MD	15	Y N	① ② ③ ④ ⑤	A B C
Leg Vein Disease, Todd V. Cartee, MD	15	Y N	① ② ③ ④ ⑤	A B C
Question and Answer	10	Y N		
Discussion of Top 3 ADC Posters, Lisa K. Pappas-Taffer, MD	25	Y N	① ② ③ ④ ⑤	A B C
Closing Remarks, Mark Abdelmalek, MD & Ellen J. Kim, MD	5	Y N	① ② ③ ④ ⑤	

OVERALL EVALUATION

Respond to the following questions regarding the overall conference.

1. Please rate your scope of knowledge regarding the topics and cases presented at 2015 Atlantic Derm PRIOR TO participating in this conference:	Little Knowledge → Extensive Knowledge ① ② ③ ④ ⑤				
2. Please rate your scope of knowledge regarding the topics and cases presented at 2015 Atlantic Derm AFTER participating in this conference:	Little Knowledge → Extensive Knowledge ① ② ③ ④ ⑤				
3. Did you feel that this CME activity was free of commercial bias for or against any commercial product?	Y N				
If no, please list speaker name and explain:					
	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
4. What I learned in this activity has increased my confidence in evaluating dermatological abnormalities.	①	②	③	④	⑤
5. What I learned in this activity will enhance my ability to change my patient management approaches.	①	②	③	④	⑤
6. What I learned in this activity will result in improvement in my patients' health status.	①	②	③	④	⑤
7. Overall, this activity was excellent.	①	②	③	④	⑤
8. Additional Comments:					